No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma

Gaetano Bacci, Loretta Loro, Alessandra Longhi, Franco Bertoni, Patrizia Bacchini, Michela Versari, Piero Picci, Massimo Serra

Research output: Contribution to journalArticle

Abstract

Our objectives were to evaluate the behavior of different doses of pre-operative methotrexate (MTX) pharmacokinetics, and assess correlations between the osteosarcoma histologic response and MTX serum peak concentrations. In total, 336 patients with osteosarcoma of the extremities were treated with three neoadjuvant protocols of chemotherapy including high-dose MTX (different doses for each protocol), cisplatin and doxorubicin (same doses in all protocols). The doses of MTX were 8 g/m in 124 patients, 10 g/m in 110 patients and 12 g/m in 102 patients. The mean value of peak serum MTX was 801 μmol/l (range 298-1831) with significant intra- and inter-patient variability. For patients treated with 8, 10 and 12 g/m it was 587, 735 and 1114 μmol/l, respectively (P

Original languageEnglish
Pages (from-to)411-415
Number of pages5
JournalAnti-Cancer Drugs
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2006

Keywords

  • Chemotherapy
  • Histologic response
  • Methotrexate
  • Osteosarcoma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma'. Together they form a unique fingerprint.

  • Cite this